NSE filing, NSE: RUBICON. Summary written from the filing by ALFA Finder's alert engine.
Rubicon Research Ltd: key numbers
- Share price
- ₹1,564.00
- Market cap
- ₹25,889 Cr
- Revenue (annual)
- ₹1,754 Cr
- Net profit (annual)
- ₹246.7 Cr
- P/E (TTM)
- 89.8×Sector 46.1×
- Promoter holding
- 51.25%-8.51% QoQ
- FII holding
- 9.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Rubicon Research Ltd
All →Rubicon Research Board Meeting Date
Rubicon Research scheduled its Board for November 5, 2026, to consider unaudited financial results for the half year ended September 2026. Trading window closed since October 1.
Rubicon Research Other Announcement
Rubicon Research Ltd filed its quarterly shareholding pattern for the quarter ended September 30, 2026, pursuant to Regulation 31(1)(b) of the LODR Regulations.
Rubicon Research Business Update
Rubicon Research reported the conclusion of a US FDA inspection at its Satara facility. The audit yielded one procedural observation unrelated to data integrity.
Rubicon Research Employee Stock Options
Rubicon Research allotted 7,200 equity shares under its Employee Stock Option Scheme 2022. This issuance marginally increases the company's total paid-up share capital.
Rubicon Research Capital Structure Change
Employee Girish Subramaniam Iyer sold 6,796 shares in the open market across four transactions for a total consideration of ₹1.23 Crore.
- Value
- ₹1.23 Cr
Rubicon Research Other Announcement
Employee Vinayak Sawant sold 1,100 shares of Rubicon Research Ltd worth ₹0.20 Crore. This disclosure is a routine regulatory filing under PIT regulations.
- Value
- ₹0.20 Cr
Other employee stock options announcements
All →Aye Finance Employee Stock Options
Aye Finance's employee welfare trust transferred 89,501 equity shares to grantees on exercising ESOP options. The share capital remains unchanged, so no new issuance occurs.
Aarti Pharmalabs Employee Stock Options
Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.
OnEMI Technology Solutions Employee Stock Options
OnEMI Technology allotted 69,000 equity shares on exercise of employee stock options under the Kissht ESOP 2022 plan. The shares rank pari passu with existing equity.
Bliss GVS Pharma Employee Stock Options
Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.
Bandhan Bank Employee Stock Options
Bandhan Bank's board granted 32,98,871 stock options under ESOP Series 1 (Tranche 9) at Rs 151.91 per option. The options vest over four years, with each option convertible into one equity share.
Maxvolt Energy Industries Employee Stock Options
Maxvolt Energy granted 5,01,726 ESOPs to six employees under its MEIL ESOP 2025 scheme at exercise prices of ₹30 and ₹45. Options vest over four years, with exercise windows following vesting.
- Execution
- Vesting over 4 years from grant (25% at 2nd, 25% at 3rd, 50% at 4th anniversary); exercise over 3 years from each vesting date